Attached files
| file | filename |
|---|---|
| EX-99.1 - EXHIBIT 99.1 - Tobira Therapeutics, Inc. | d18467dex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 17, 2015
Tobira Therapeutics, Inc.
(Exact name of registrant as specified in its charter)
| Delaware | 001-35953 | 03-0422069 | ||
| (State or other Jurisdiction of Incorporation) |
(Commission File No.) |
(IRS Employer Identification No.) |
701 Gateway Blvd, Suite 300
South San Francisco, CA 94080
(Address of principal executive offices, including zip code)
(650) 741-6625
(Registrant’s telephone number, including area code)
(Former Name or Former Address, if Changed Since Last Report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2):
| ¨ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| ¨ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| ¨ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| ¨ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
| Item 8.01. | Other Events. |
On August 17, 2015, Tobira Therapeutics, Inc. issued a press release to announce that it enrolled its first patient in the Phase 2a ORION study, which is a randomized, double-blind, placebo-controlled study evaluating the treatment effects of cenicriviroc (CVC) in approximately 50 obese adults (BMI ³ 30 kg/m2) with prediabetes or diabetes and suspected non-alcoholic fatty liver disease (NAFLD).
A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.
Item 9.01 Financial Statements and Exhibits.
(d) Exhibits
| Exhibit |
Description | |
| 99.1 | Press Release titled “Tobira Therapeutics Announces Initiation of ORION, a Phase 2a Study of Cenicriviroc in Obese Patients with Suspected Fatty Liver Disease,” dated August 17, 2015 | |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| Tobira Therapeutics, Inc. | ||
| By: | /s/ Laurent Fischer, M.D. | |
| Laurent Fischer, M.D. | ||
| Chief Executive Officer | ||
Dated: August 17, 2015